Kyle LaHucik

BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG

BrainChild Bio raised $116 million in a Series A to fund a pivotal trial of a B7-H3–targeted CAR-T therapy for pediatric diffuse intrinsic pontine glioma (DIPG), aiming to make CAR-Ts function more like small molecules for brain tumors.